Eli Lilly and Co at UBS Global Healthcare Virtual Conference Transcript

May 26, 2021 / 02:00PM GMT
Navin Cyriac Jacob - UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

Good morning and close to good afternoon, but my name is Navin Jacob. I'm with UBS. Thank you for joining our UBS Global Healthcare Conference. I'm the senior analyst covering SMID-cap biotech and large-cap pharma here at UBS.

I'm happy to have with us for our next session, Eli Lilly and Company. And from Lilly, we have CFO, Anat Ashkenazi. Anat, thank you for joining us today.

Anat Ashkenazi - Eli Lilly and Company - Senior VP & CFO

Great. Thanks. Good to be here, Navin. Good morning, everyone.

Questions and Answers:

Navin Cyriac Jacob - UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

Fantastic. So we're going to have a fireside chat here with Q&A between you and me. But I do want to actually ask audience members to please feel free to participate, ask questions via the chat
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot